RPRX Valuation

Royalty Pharma PLC

Add to Watchlist

Advanced Chart

36.010

-0.09(-0.249%)1D

Overview
Forecast
Valuation
Earnings

RPRX Relative Valuation

RPRX's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, RPRX is overvalued; if below, it's undervalued.

Historical Valuation

Royalty Pharma PLC (RPRX) is now in the Undervalued zone, suggesting that its current forward PE ratio of 7.77 is considered Undervalued compared with the five-year average of 10.57. The fair price of Royalty Pharma PLC (RPRX) is between 43.52 to 69.51 according to relative valuation methord. Compared to the current price of 36.10 USD , Royalty Pharma PLC is Undervalued By 17.05%.

Relative Value

Fair Zone

43.52-69.51

Current Price：36.10

17.05%

Undervalued

Trailing

Forward

P/E

EV/EBITDA

EV/EBIT

P/S

P/OCF

P/FCF

Trailing

Forward

2.30

P/B

Median3y

2.27

Median5y

2.67

17.98

FCF Yield

Median3y

18.85

Median5y

16.09

Competitors Valuation Multiple

The average P/S ratio for RPRX's competitors is 64.84, providing a benchmark for relative valuation. Royalty Pharma PLC Corp (RPRX) exhibits a P/S ratio of 4.88, which is -92.48% above the industry average. Given its robust revenue growth of 0.05%, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap